Estimating typical multiple sclerosis disability progression speed from clinical observations

PLoS ONE

Volumn 9, Issue 10, 2014, Pages

  Brown, Murray G ^a   Asbridge, Mark ^a   Hicks, Vern ^a   Kirby, Sarah ^a   Murray, Thomas J ^a   Andreou, Pantelis ^a   Lin, Dong ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; GLATIRAMER; INTERFERON BETA SERINE;

ARTICLE; CANADA; CENSORING BIAS; CLINICAL OBSERVATION; DISABILITY; DISEASE COURSE; EXPANDED DISABILITY STATUS SCALE; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE SCLEROSIS; PROGNOSIS; STATISTICAL ANALYSIS; STATISTICAL BIAS; SURVIVAL TIME; PATHOLOGY;

DISABILITY EVALUATION; DISEASE PROGRESSION; HUMANS; MULTIPLE SCLEROSIS; NOVA SCOTIA;

EID: 84908439556     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0105123     Document Type: Article

References (48)

1. Hougaard P (2000) Analysis of multivariate survival data. Springer-Verlag, New York.
2. Leung KM, Elashoff RM, Afifi AA (1997) Censoring issues in survival analysis. Annu Rev Public Health; 18: 83-104.
3. Mallinckrodt CH, Kenward MG (2009) Conceptual Considerations Regarding Endpoints, Hypotheses, and Analyses for Incomplete Longitudinal Clinical Trial Data. Drug Information Journal; 43: 449-458.
4. Samuelsen SO, Kongerud J (1994) Interval censoring in longitudinal data of respiratory symptoms in aluminium potroom workers: a comparison of methods. Stat Med; 13: 1771-80.
5. Fowke KR, Nagelkerke NJD, Kimani J, Simonsen JN, Anzala AO, et al. (1996) Resistance to HIV-1 infection among persistently sernegative prostitutes in Nairobi, Kenya. The Lancet; 348(9039): 1347-52.
6. Banglmaier RF, Wang L, Prasad P (2006) Influence of interval censoring and bias on injury risk curve development. Int J Mater Prod Tec; 25(1): 42-63.
7. Viel JF, Curbakova E, Dzerve B, Eglite M, Zvagule T, et al. (1997) Risk factors for long-term mental and psychosomatic distress in Latvian Chernobyl liquidators. Environ Health Perspect; 105: 1539-44.
8. Zhao Y, Frey C (2004) Quantification of variability and uncertainty for censored data sets and application to air toxic emission factors. Risk Anal; 24(4): 1019-34.
9. Tan X, Dierker L, Rose J, Li R (2011) How spacing of data collection may impact estimates of substance use trajectories. Subst Use Misuse; 46: 758-68.
10. Lantz PM, Booth KM (1998) The social construction of the breast cancer epidemic. Soc Sci Med; 46(7): 907-18.
11. Paty DW, Ebers GC (1998) Multiple sclerosis. Philadelphia: F. A. Davis Company.
12. Murray TJ (2009) The history of multiple sclerosis: the changing frame of the disease over the centuries. J Neurol Sci; 277 Suppl 1: S3-8.
13. Eriksson M, Andersen O, Runmarker B (2003) Long-term follow up of patients with clinically isolated syndromes, relapsing remitting and secondary progressive multiple sclerosis. Mult Scler; 9: 260-274.
14. Bronnum-Hansen H, Koch-Henriksen N, Stenager E (2004) Trends in survival and cause of death in Danish patients with multiple sclerosis. Brain; 127: 844-850.
15. Ebers GC (2005) Prognostic factors for multiple sclerosis: the importance of natural history studies. J Neurol; 252 Suppl 3: iii15-20.
16. Confavreux C, Compston A (2006) The natural history of multiple sclerosis. In: Compston A, Confavreux C, Lassmann H, et al, editors. McAlpine's Multiple Sclerosis, 4th ed. London: Churchill Livingstone Elsevier.
17. Kremenchutzky M, Rice GP, Baskerville J, Wingerchuk DM, Ebers GC (2006) The natural history of multiple sclerosis: a geographically based study 9: observations on the progressive phase of the disease. Brain; 129: 584-594.
18. Montalban X (2006) The importance of long-term data in multiple sclerosis. J Neurol; 253 Suppl 6: vi9-vi15.
19. Tremlett H, Paty D, Devonshire V (2006) Disability progression in multiple sclerosis is slower than previously reported. Neurology; 66(2): 172-7.
20. Debouverie M, Louis S, Pittion-Vouyovitch S, Roederer T, Vespignani H (2007) Multiple sclerosis with a progressive course from onset in Lorraine-Eastern France. J Neurol; 254: 1370-1375.
21. McLeod JG, Barnett MH, Macaskill P, Williams DB (2007) Long-term prognosis of multiple sclerosis in Australia. J Neurol Sci; 256: 35-38.
22. Trojano M, Pelligrini F, Fuiani A (2007) New natural history of interferon-beta-treated relapsing multiple sclerosis. Ann Neurol; 61: 300-6.
23. Brown MG, Kirby S, Skedgel C, Fisk JD, Murray TJ, et al. (2007) How effective are disease-modifying drugs in delaying progression in relapsing-onset MS? Neurology; 69(15): 1498-507.
24. Trojano M (2007) Is it time to use observational data to estimate treatment effectiveness in multiple sclerosis? Neurology; 69: 1478-9.
25. Tremlett H, Zhao Y, Devonshire V (2008) Defining the natural history of MS: the need for complete data and rigorous definitions. Mult Scler; 14(8): 1142-3; author reply 1144-7.
26. Costelloe L, Thompson A, Walsh C, Tubridy N, Hutchinson M (2008) Long-term clinical relevance of criteria for designating multiple sclerosis as benign after 10 years of disease. J Neurol Neurosurg Psychiatry; 79: 1245-1248.
27. Koch M, Uyttenboogaart M, Heerings M, Heersema D, Mostert J, et al. (2008) Progression in familial and nonfamilial MS. Mult Scler; 14: 300-306.
28. Brown M, Andreou P, Kirby S, Murray J (2008) EDSS natural history atlas: MS disability progression in Nova Scotia1979-2004: ECTRIMS Conference, Montreal, Sept. 17-20, 2008. Mult Scler; 14 (suppl 1): abstract P540.
29. Grytten Torkildsen N, Lie SA, Aarseth JH, Nyland H, Myhr KM (2008) Survival and cause of death in multiple sclerosis: results from a 50-year follow-up in Western Norway. Mult Scler; 14: 1191-1198.
30. Veugelers PJ, Fisk JD, Brown MG, Stadnyk K, Sketris IS, et al. (2009) Disease progression among multiple sclerosis patients before and during a disease-modifying drug program: A longitudinal population-based evaluation. Mult Scler; 15 1286.
31. Tremlett H, Zhao Y, Rieckmann P, Hutchinson M (2010) New perspectives in the natural history of multiple sclerosis. Neurology; 74(24): 2004-15.
32. Bergamaschi R, Quaglini S, Tavazzi E, Amato MP, Paolicelli D, et al. (2012) Immunomodulatory therapies delay disease progression in multiple sclerosis. Mult Scler; 14(1). Available: http://msj.sagepub.com/content/early/2012/05/31/135245851244594.pdf. Accessed: 2014 Aug 6.
33. Shirani A, Zhao Y, Karim ME, Evans C, Kingwell E, et al. (2012) Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis. JAMA; 308(3): 247-56.
34. Derfuss T, Kappos L (2012) Evaluating the potential benefit of interferon treatment in multiple sclerosis. JAMA; 308: 290-1.
35. Kurtzke JF (1955) A new scale for evaluating disability in multiple sclerosis. Neurology; 5(8): 580-3.
36. Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology; 33: 1444-52.
37. Herndon RM (2006) Handbook of neurologic rating scales. 2nd ed. New York: Demos Medical.
38. Kurtzke JF (2000) Why at the present time does EDSS scale remain a preferred outcome measure to evaluate disease evolution? Neurol Sci; 21(6): 339-41.
39. Kurtzke JF (2008) Historical and clinical perspectives of the expanded disability status scale. Neuroepidemiology; 31(1): 1-9.
40. Fisk JD, Brown MG, Sketris IS, Metz LM, Murray TJ, et al. (2005) A comparison of health utility measures for the evaluation of multiple sclerosis treatments. J Neurol Neurosurg Psychiatry; 76(1): 58-63.
41. Poser CM, Paty DW, Scheinberg L (1983) New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol; 13(3): 227-31.
42. Poser CM, Brinar VV (2004) Diagnostic criteria for multiple sclerosis: an historical review. Clin Neurol Neurosurg; 106(3): 147-58.
43. McDonald WI, Compston A, Edan G (2001) Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol; 50(1): 121-7.
44. Brown MG, Andreou P, Lin D, Lethbridge L (2013) Computing expected survival times from incomplete observations (SAS code) [computer program]. Halifax, NS: Dalhousie University.
45. SAS (2008) Institute Inc. SAS Statistical Software [computer program]. Release 9.2. Cary, NC: SAS Institute Inc.
46. Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc; 53: 457-81.
47. Becker RV, Dembek MS (2011) Effects of Cohort Selection on the Results of Cost-Effectiveness Analysis of Disease-Modifying Drugs for Relapsing-Remitting Multiple Sclerosis. J Manag Care Pharm; 17(5): 377-81.
48. Bhan V, Brown MG, Fisk JD, Murray TJ, Sketris IA, et al. (2005) Prevalence estimates of multiple sclerosis in Nova Scotia [abstract]. ECTRIMS 2005 Proceedings, Thessaloniki, Greece. Mult Scler; 11 Suppl 1: P406.